CINCINNATI, Dec. 29 (UPI) -- Researchers at Cincinnati Children's Hospital Medical Center have found a new way to target the treatment of pre-malignant disorders called myelodysplasia syndromes, or MDS.
MDS is a group of pre-malignant disorders in bone marrow that inhibit the production of healthy blood cells and can lead to acute myeloid leukemia, or AML.